Journal of Bone and Mineral Research 2015; Volume 30, Issue 6, pages 951–966 The goal of this review is to clarify the biomechanical mechanisms and to make recommendations for systematically evaluating phenotypic changes in mouse … Leer más
Journal of Bone and Mineral Research 2015; Volume 30, Issue 6, pages 970–975 The data show that hyponatremia is associated with up to a doubling in the risk of hip and morphometric spine fractures, independent … Leer más
Bone. 2015 May 16. pii: S8756-3282(15)00195-7. doi: 10.1016/j.bone.2015.05.016. Although TBS changes with osteoporosis treatment, the magnitude is less than that of aBMD of the spine, and it is not clear how change in TBS relates … Leer más
J Bone Miner Res. 2015 May;30(5):929-33. doi: 10.1002/jbmr.2410. We conclude that the effects of bisphosphonates on fracture prevention in osteogenesis imperfecta are inconclusive. Adequately powered trials with a fracture endpoint are needed to further investigate … Leer más
J Bone Miner Res. 2015 May;30(5):934-44. doi: 10.1002/jbmr.2442. The results suggest almost all patients who have received six annual ZOL infusions can stop medication for up to 3 years with apparent maintenance of benefits. Autor: … Leer más
COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.
Our data suggest that Glu-OCN-controlled production of Delta like-1 (DLK1) by pancreatic β cells acts as a negative feedback mechanism to counteract the stimulatory effects of insulin on osteoblast production of Glu-OCN, a potential mechanism … Leer más
Prescribed medicines and potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) prevalence were high among patients 85 years and over. Benzodiazepine use in those who are prone to falls and omission of calcium and … Leer más
DALY losses were considerable amongst postmenopausal women with osteoporosis. Not having a prior bone fracture, being older, using a SERM and having less osteoporotic risk factors were all linked to less DALY losses.
In postmenopausal women, bisphosphonates have not been shown to better decrease risk of first fracture compared with calcium and vitamin D therapy alone.
